Credit: Shutterstock photo. Less than 40% of the 2014 and 2015 classes are above water at this point. (Actualisé avec du contexte, cours de Bourse) LONDRES, 6 novembre (Reuters) - AstraZeneca AZN.L a annoncé vendredi qu'il achetait la société biotechnologique américaine ZS Pharma ZSPH Todd was the CFO and led business development activities for Sarcode which developed lifitigrast, the first dry-eye pharmaceutical to be approved (2016) for both signs and symptoms of dry eye (sold to Shire in 2013). Our core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions. Stock for Coppell-based ZS Pharma opened on the NASDAQ well above its planned range of $15 to $17. - Renaissance Capital - Renaissance Capital IPO Investing The ZS Pharma transaction is expected to close by the end of this year. ZS Pharma’s biotech IPO is the first one from Texas since 2000, when there were four, according to Kathleen Smith, a principal at the research firm Renaissance Capital. ZS Pharma (NASDAQ:ZSPH) Share Price and News. ZS Pharma’s filing got me looking for the last Texas life sciences firm to hit the public markets. Prior to that, he was CFO and Treasurer of ZS Pharma (IPO in 2014 and sold to AstraZeneca in 2015; a 30x increase in valuation from when he joined in 2013). 13 - Material Contract - Accession Number 0001193125-14-199541 - Filing - SEC ZS Pharma Inc. (Coppell, Texas) filed to raise up to $86.3 Read the full 110 word article Contributor . - Renaissance Capital ZS Pharma, a late-stage biotech developing a treatment for hyperkalemia, filed on Thursday with the SEC to raise up to $86 million in an initial public offering. ZS Pharma, founded in 2008, is a publicly traded biopharmaceutical company dedicated to challenging the status quo in disease states where therapeutic options have been limited. A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; Q; R; S; T; U; V; W; X; Y; Z; Services ZS Pharma, a late-stage biotech developing a treatment for hyperkalemia, filed on Thursday with the SEC to raise up to $86 million in an initial. Xconomy. Read Next ZS Pharma received $2 million from the state in 2010 under the Emerging Technology Fund and began trading in June 2014 in an initial public offering that raised more than $106 million. (Boursier.com) — Olivier Nataf, Président d'AstraZeneca France, annonce la nomination d'Isabelle Laforgue, au poste de directrice "Digital, Transformation et Innovation". ZS Pharma was founded in the Fort Worth suburb of Coppell, TX, and relocated to San Mateo, CA following the company’s $107 million IPO last year. ZS Pharma is funded by 10 investors. AstraZeneca Buying ZS Pharma On Eve Of Drug Data Drop. ZS Pharma, a late-stage biotech developing a treatment for excess potassium (hyperkalemia), raised $107 million by offering 5. Search by Last Name . ZS Pharma raised nearly $107 million on the NASDAQ capital market from its IPO yesterday. ZS Pharma moved to Fort Worth in order to get funding from the Texas Emerging Technology Fund. ZS Pharma prices IPO at $18, above the range. ZS Pharma has raised a total of $123M in funding over 5 rounds. Biotechs all over the country have been rushing into the IPO queue over the last year—just, as it turns out, not in Texas. ZS Pharma is executing a familiar biotech gambit. About Kiniksa Kiniksa is a biopharmaceutical company with an experienced team that has advanced multiple product candidates in parallel that focus on a range of debilitating diseases with significant unmet medical need. Z S Pharma… RiverVest and Salem Partners are the most recent investors. We are currently focused on using our proprietary ion-trap technology to develop new treatments that are focused on addressing unmet needs in the medical community. BRIAN DEAGON; 05:50 PM ET 02/20/2015 Related news. Biontech and ADC Therapeutics stand out among a number of sizeable flotations heading towards Nasdaq, seeking to raise around $250m and $200m respectively; IGM Biosciences raised $200m last week, after upsizing its offering. The … ZS Pharma, Inc. (US:ZSPH) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. May 20, 2014. The company'ss therapeutic candidate, ZS-9, is a novel treatment for hyperkalemia, a life-threatening condition That changed this past week, when ZS Pharma, a suburban Fort Worth, TX, biotech, revealed plans to go public and raise as much as $86 million from investors. These … by John Carroll | May 15, 2014 10:01am. ZS Pharma Ends Texas Biotech IPO Dry Spell With $86M Pitch . Lokelma works as an oral potassium-removing agent. ZS Pharma… IPO Stock Watch: Biotech ZS Pharma Hits New High Licensing. ZS Pharma is a privately held specialty pharmaceutical company based in Coppell, Texas, and Menlo Park, CA. IPO Stock Watch: Biotech ZS Pharma Soars 55% In IPO Licensing. ZS Pharma looks to $86M IPO to fund PhIII hyperkalemia studies. Early-stage biotechs have been able to … Prior to HealthQuest, he was the Chief Financial Officer and Treasurer of ZS Pharma (IPO in 2014 and sold to AstraZenaca in 2015). We continue to explore expanding our pipeline in order to develop life-changing medicines for patients who need it most. Its core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions. He previously served on the boards of Lumena Pharmaceuticals, Inc. (acquired by Shire Plc), Otonomy, Inc. (IPO) and ZS Pharma, Inc. (acquired by AstraZeneca Plc). ZS Pharma, Inc. - IPO: ‘S-1’ on 5/14/14 - EX-10.14 Registration Statement (General Form) - Seq. But when Actelion sounded out ZS back in September there were questions over whether a takeover would present a true strategic fit or simply a case of trying to buy in a promising-looking company (Hyperkalaemia comes into play for Actelion, September 11, 2015). For the 2018, IPO class 58% of them remain above their IPO price. Their latest funding was raised on Jul 18, 2014 from a Post-IPO Debt round. ZS Pharma expects to raise $71.9 million in IPO (June 13, 2014) - ZS Pharma Inc., a late-stage biopharmaceutical company developing drugs to treat hyperkalemia, said it expects to raise $71.9 million in an initial public offering after underwriting costs and offering expenses. Jun 17, 2014 6:19AM EDT. BRIAN DEAGON; 02:09 PM ET 06/18/2014 Related news Energy Stocks And Industry News: Oil, … With the IPO window still open for small drug developers, companies are making the most of the opportunity while it lasts. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. 10 Mar. The drug joined AstraZeneca’s portfolio when the company acquired its original developer ZS Pharma in 2015 for $2.7 billion. It was the first Texas-based biotech IPO in more than a decade. ZS Pharma stock roared higher after the Bloomberg report, closing with a 28.4% gain at $74.73 that pushed the company's market cap closer to $2 billion. ZS Pharma is registered under the ticker NASDAQ:ZSPH . ZS Pharma, founded in 2008, is a privately held specialty pharmaceutical company based in Coppell, Texas and Menlo Park, CA. Their stock opened with $27.00 in its Jun 19, 2014 IPO. Renaissance Capital Renaissance Capital Published. Upcoming Events. Relypsa would be cheaper; at $781m its market cap is around half that of ZS Pharma.
Quark Mit Früchten Kalorienarm, Coral Beach Hotel Restaurants, Pfizer Vs Moderna Vaccine, Online-banking Pin Sparkasse, Atemlos Gefährliche Wahrheit Hdfilme, Frank Grillo Movies 2020, B3 Unfall Heute, Zwangsversteigerungen Amtsgericht Montabaur, Unfall Großerlach Mainhardt,